Please assess the completion status of the following clinical trial:

Trial Title: Benign Prostatic Hyperplasia and Ischemic Heart DIsease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* LUTS/BPH, with the total score by the IPSS more than or equal to 8;~* Functional class II-IV angina of effort;~* Non-ST segment depression postinfarction cardiosclerosis.~Exclusion Criteria:~* Presence of cystostomic drainage;~* Long-term LUTS/BPH therapy of prostatic hyperplasia (alpha-adrenoblockers, 5-alpha-reductase inhibitors and others) - for the groups of patients of conservative treatment of BPH;~* Patients after operative treatment of prostatic hyperplasia (TUR of prostatic hyperplasia, transvesical adenomectomy, etc.);~* Urinary bladder stones;~* Acute urinary retention;~* Changes on the ECG hampering its interpretation (complete left bundle branch block, cicatricial changes after endured myocardial infarction, permanent form of ciliary arrhythmia);~* Acute forms of ischaemic heart disease.

- Gender: MALE
- Minimum Age: 57 Years
- Maximum Age: 81 Years
- Healthy Volunteers: f

Study Arms:
- No intervention (Type: NO_INTERVENTION): It included the patients in whom during urination certain changes in HM were registered. The Group 1 patients' age varied from 63 to 79 years (mean 68.6±4.94 years). Nearly all except two patients (cardiac background of these patients did not require medical or surgical correction) from this group received cardiotropic therapy which did not change during one-month follow-up.
- Tamsulosin (Type: ACTIVE_COMPARATOR): This group enrolled 28 patients in whom primary HM detected certain alterations (VE, SVE, ST segment depression) which did not coincide with the act of urination. The age of patients was from 57 to 81 years (mean 71.3±1.1 years). In order to improve impaired urination were also received Tamsulosin at a dose of 0.4 mg once daily (in the morning) for the whole period of follow up and treatment. Tamsulosin Oral Capsule.
- TURP (Type: ACTIVE_COMPARATOR): This group was composed of patients for whom after examination for symptoms of IHD and LUTS/BPH a decision was made on the necessity to perform operative treatment of BPH. TURP operation was indicated due to pronounced urination disorders which were most important amongst the patient's complaints. The patients' age varied from 59 to 77 years (mean 67.5±2.1 years).

Based on this trial design, predict the completion outcome and termination type (if applicable).